Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach

Dafni Moschidou, Sayandip Mukherjee, Michael P. Blundell, Katharina Drews, Gemma N. Jones, Hassan Abdulrazzak, Beata Nowakowska, Anju Phoolchund, Kenneth Lay, T. Selvee Ramasamy, Mara Cananzi, Daniel Nettersheim, Mark Sullivan, Jennifer Frost, Gudrun Moore, Joris R. Vermeesch, Nicholas M. Fisk, Adrian J. Thrasher, Anthony Atala, James Adjaye & 3 others Hubert Schorle, Paolo De Coppi, Pascale V. Guillot

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Induced pluripotent stem cells (iPSCs) with potential for therapeutic applications can be derived from somatic cells via ectopic expression of a set of limited and defined transcription factors. However, due to risks of random integration of the reprogramming transgenes into the host genome, the low efficiency of the process, and the potential risk of virally induced tumorigenicity, alternative methods have been developed to generate pluripotent cells using nonintegrating systems, albeit with limited success. Here, we show that c-KIT human first-trimester amniotic fluid stem cells (AFSCs) can be fully reprogrammed to pluripotency without ectopic factors, by culture on Matrigel in human embryonic stem cell (hESC) medium supplemented with the histone deacetylase inhibitor (HDACi) valproic acid (VPA). The cells share 82% transcriptome identity with hESCs and are capable of forming embryoid bodies (EBs) in vitro and teratomas in vivo. After long-term expansion, they maintain genetic stability, protein level expression of key pluripotency factors, high cell-division kinetics, telomerase activity, repression of X-inactivation, and capacity to differentiate into lineages of the three germ layers, such as definitive endoderm, hepatocytes, bone, fat, cartilage, neurons, and oligodendrocytes. We conclude that AFSC can be utilized for cell banking of patient-specific pluripotent cells for potential applications in allogeneic cellular replacement therapies, pharmaceutical screening, and disease modeling.

Original languageEnglish
Pages (from-to)1953-1967
Number of pages15
JournalMolecular Therapy
Volume20
Issue number10
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Fingerprint

Valproic Acid
Amniotic Fluid
Transgenes
Stem Cells
Embryoid Bodies
Germ Layers
Induced Pluripotent Stem Cells
X Chromosome Inactivation
Endoderm
Histone Deacetylase Inhibitors
Protein Stability
Telomerase
Teratoma
Oligodendroglia
First Pregnancy Trimester
Transcriptome
Cell Division
Cartilage
Hepatocytes
Transcription Factors

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Moschidou, D., Mukherjee, S., Blundell, M. P., Drews, K., Jones, G. N., Abdulrazzak, H., ... Guillot, P. V. (2012). Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. Molecular Therapy, 20(10), 1953-1967. https://doi.org/10.1038/mt.2012.117

Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. / Moschidou, Dafni; Mukherjee, Sayandip; Blundell, Michael P.; Drews, Katharina; Jones, Gemma N.; Abdulrazzak, Hassan; Nowakowska, Beata; Phoolchund, Anju; Lay, Kenneth; Ramasamy, T. Selvee; Cananzi, Mara; Nettersheim, Daniel; Sullivan, Mark; Frost, Jennifer; Moore, Gudrun; Vermeesch, Joris R.; Fisk, Nicholas M.; Thrasher, Adrian J.; Atala, Anthony; Adjaye, James; Schorle, Hubert; De Coppi, Paolo; Guillot, Pascale V.

In: Molecular Therapy, Vol. 20, No. 10, 01.10.2012, p. 1953-1967.

Research output: Contribution to journalArticle

Moschidou, D, Mukherjee, S, Blundell, MP, Drews, K, Jones, GN, Abdulrazzak, H, Nowakowska, B, Phoolchund, A, Lay, K, Ramasamy, TS, Cananzi, M, Nettersheim, D, Sullivan, M, Frost, J, Moore, G, Vermeesch, JR, Fisk, NM, Thrasher, AJ, Atala, A, Adjaye, J, Schorle, H, De Coppi, P & Guillot, PV 2012, 'Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach', Molecular Therapy, vol. 20, no. 10, pp. 1953-1967. https://doi.org/10.1038/mt.2012.117
Moschidou D, Mukherjee S, Blundell MP, Drews K, Jones GN, Abdulrazzak H et al. Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. Molecular Therapy. 2012 Oct 1;20(10):1953-1967. https://doi.org/10.1038/mt.2012.117
Moschidou, Dafni ; Mukherjee, Sayandip ; Blundell, Michael P. ; Drews, Katharina ; Jones, Gemma N. ; Abdulrazzak, Hassan ; Nowakowska, Beata ; Phoolchund, Anju ; Lay, Kenneth ; Ramasamy, T. Selvee ; Cananzi, Mara ; Nettersheim, Daniel ; Sullivan, Mark ; Frost, Jennifer ; Moore, Gudrun ; Vermeesch, Joris R. ; Fisk, Nicholas M. ; Thrasher, Adrian J. ; Atala, Anthony ; Adjaye, James ; Schorle, Hubert ; De Coppi, Paolo ; Guillot, Pascale V. / Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. In: Molecular Therapy. 2012 ; Vol. 20, No. 10. pp. 1953-1967.
@article{060d245d3c614cccad81a294ce199ad8,
title = "Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach",
abstract = "Induced pluripotent stem cells (iPSCs) with potential for therapeutic applications can be derived from somatic cells via ectopic expression of a set of limited and defined transcription factors. However, due to risks of random integration of the reprogramming transgenes into the host genome, the low efficiency of the process, and the potential risk of virally induced tumorigenicity, alternative methods have been developed to generate pluripotent cells using nonintegrating systems, albeit with limited success. Here, we show that c-KIT human first-trimester amniotic fluid stem cells (AFSCs) can be fully reprogrammed to pluripotency without ectopic factors, by culture on Matrigel in human embryonic stem cell (hESC) medium supplemented with the histone deacetylase inhibitor (HDACi) valproic acid (VPA). The cells share 82{\%} transcriptome identity with hESCs and are capable of forming embryoid bodies (EBs) in vitro and teratomas in vivo. After long-term expansion, they maintain genetic stability, protein level expression of key pluripotency factors, high cell-division kinetics, telomerase activity, repression of X-inactivation, and capacity to differentiate into lineages of the three germ layers, such as definitive endoderm, hepatocytes, bone, fat, cartilage, neurons, and oligodendrocytes. We conclude that AFSC can be utilized for cell banking of patient-specific pluripotent cells for potential applications in allogeneic cellular replacement therapies, pharmaceutical screening, and disease modeling.",
author = "Dafni Moschidou and Sayandip Mukherjee and Blundell, {Michael P.} and Katharina Drews and Jones, {Gemma N.} and Hassan Abdulrazzak and Beata Nowakowska and Anju Phoolchund and Kenneth Lay and Ramasamy, {T. Selvee} and Mara Cananzi and Daniel Nettersheim and Mark Sullivan and Jennifer Frost and Gudrun Moore and Vermeesch, {Joris R.} and Fisk, {Nicholas M.} and Thrasher, {Adrian J.} and Anthony Atala and James Adjaye and Hubert Schorle and {De Coppi}, Paolo and Guillot, {Pascale V.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1038/mt.2012.117",
language = "English",
volume = "20",
pages = "1953--1967",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach

AU - Moschidou, Dafni

AU - Mukherjee, Sayandip

AU - Blundell, Michael P.

AU - Drews, Katharina

AU - Jones, Gemma N.

AU - Abdulrazzak, Hassan

AU - Nowakowska, Beata

AU - Phoolchund, Anju

AU - Lay, Kenneth

AU - Ramasamy, T. Selvee

AU - Cananzi, Mara

AU - Nettersheim, Daniel

AU - Sullivan, Mark

AU - Frost, Jennifer

AU - Moore, Gudrun

AU - Vermeesch, Joris R.

AU - Fisk, Nicholas M.

AU - Thrasher, Adrian J.

AU - Atala, Anthony

AU - Adjaye, James

AU - Schorle, Hubert

AU - De Coppi, Paolo

AU - Guillot, Pascale V.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Induced pluripotent stem cells (iPSCs) with potential for therapeutic applications can be derived from somatic cells via ectopic expression of a set of limited and defined transcription factors. However, due to risks of random integration of the reprogramming transgenes into the host genome, the low efficiency of the process, and the potential risk of virally induced tumorigenicity, alternative methods have been developed to generate pluripotent cells using nonintegrating systems, albeit with limited success. Here, we show that c-KIT human first-trimester amniotic fluid stem cells (AFSCs) can be fully reprogrammed to pluripotency without ectopic factors, by culture on Matrigel in human embryonic stem cell (hESC) medium supplemented with the histone deacetylase inhibitor (HDACi) valproic acid (VPA). The cells share 82% transcriptome identity with hESCs and are capable of forming embryoid bodies (EBs) in vitro and teratomas in vivo. After long-term expansion, they maintain genetic stability, protein level expression of key pluripotency factors, high cell-division kinetics, telomerase activity, repression of X-inactivation, and capacity to differentiate into lineages of the three germ layers, such as definitive endoderm, hepatocytes, bone, fat, cartilage, neurons, and oligodendrocytes. We conclude that AFSC can be utilized for cell banking of patient-specific pluripotent cells for potential applications in allogeneic cellular replacement therapies, pharmaceutical screening, and disease modeling.

AB - Induced pluripotent stem cells (iPSCs) with potential for therapeutic applications can be derived from somatic cells via ectopic expression of a set of limited and defined transcription factors. However, due to risks of random integration of the reprogramming transgenes into the host genome, the low efficiency of the process, and the potential risk of virally induced tumorigenicity, alternative methods have been developed to generate pluripotent cells using nonintegrating systems, albeit with limited success. Here, we show that c-KIT human first-trimester amniotic fluid stem cells (AFSCs) can be fully reprogrammed to pluripotency without ectopic factors, by culture on Matrigel in human embryonic stem cell (hESC) medium supplemented with the histone deacetylase inhibitor (HDACi) valproic acid (VPA). The cells share 82% transcriptome identity with hESCs and are capable of forming embryoid bodies (EBs) in vitro and teratomas in vivo. After long-term expansion, they maintain genetic stability, protein level expression of key pluripotency factors, high cell-division kinetics, telomerase activity, repression of X-inactivation, and capacity to differentiate into lineages of the three germ layers, such as definitive endoderm, hepatocytes, bone, fat, cartilage, neurons, and oligodendrocytes. We conclude that AFSC can be utilized for cell banking of patient-specific pluripotent cells for potential applications in allogeneic cellular replacement therapies, pharmaceutical screening, and disease modeling.

UR - http://www.scopus.com/inward/record.url?scp=84866994859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866994859&partnerID=8YFLogxK

U2 - 10.1038/mt.2012.117

DO - 10.1038/mt.2012.117

M3 - Article

VL - 20

SP - 1953

EP - 1967

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 10

ER -